Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Alpine Immune Sciences (ALPN) Stock Forecast & Price Target

Get the Latest News and Ratings for ALPN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Alpine Immune Sciences and its competitors.

Sign Up

ALPN Analyst Ratings Over Time

TypeCurrent Forecast
10/11/23 to 10/10/24
1 Month Ago
9/11/23 to 9/10/24
3 Months Ago
7/13/23 to 7/12/24
1 Year Ago
10/11/22 to 10/11/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
6 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$52.33$52.33$52.33$18.17
Forecasted Upside-19.45% Downside-19.45% Downside-19.45% Downside67.74% Upside
Consensus Rating
Hold
Hold
Hold
Buy

ALPN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALPN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Alpine Immune Sciences Stock vs. The Competition

TypeAlpine Immune SciencesMedical CompaniesS&P 500
Consensus Rating Score
2.27
2.79
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside-19.45% Downside10,995.04% Upside7.34% Upside
News Sentiment Rating
Neutral News

See Recent ALPN News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/16/2024Wedbush
3 of 5 stars
R. Driscoll
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$65.00+0.05%
4/16/2024TD Cowen
4 of 5 stars
 Reiterated RatingBuy ➝ Hold
4/12/2024Leerink Partners
1 of 5 stars
 DowngradeOutperform ➝ Market Perform$42.00 ➝ $65.00+0.87%
4/11/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
4/11/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Pantginis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
4/11/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Equal Weight$47.00 ➝ $65.00+38.18%
4/11/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Sector Perform$41.00 ➝ $65.00+38.18%
4/11/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Peer Perform
4/9/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$55.00+42.75%
3/19/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$33.00 ➝ $44.00+24.05%
10/17/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$18.00+80.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:52 AM ET.


ALPN Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Alpine Immune Sciences is $52.33, with a high forecast of $65.00 and a low forecast of $18.00.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALPN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALPN, but not buy additional shares or sell existing shares.

According to analysts, Alpine Immune Sciences's stock has a predicted downside of -19.45% based on their 12-month stock forecasts.

Analysts like Alpine Immune Sciences less than other "medical" companies. The consensus rating for Alpine Immune Sciences is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ALPN compares to other companies.


This page (NASDAQ:ALPN) was last updated on 10/10/2024 by MarketBeat.com Staff
From Our Partners